# Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

> **NCT03503344** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 26 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- PSA Progression
- Stage IV Prostate Adenocarcinoma AJCC v7

## Interventions

- **DRUG:** Apalutamide
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT03503344
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-17
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03503344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03503344, "Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03503344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*